Literature DB >> 27924473

Non-nucleotide Modification of Anti-miRNA Oligonucleotides.

Kim A Lennox1, Christopher A Vakulskas1, Mark A Behlke2.   

Abstract

MicroRNAs (miRNAs) are important modulators of gene expression. Synthetic anti-microRNA oligonucleotides (AMOs, or anti-miRs) are a form of steric-blocking antisense oligonucleotides (ASOs) that inhibit miRNA function through high-affinity binding and subsequent inactivation and/or degradation of the targeted miRNA. AMOs are a primary tool used to empirically determine the biological targets of a miRNA and can also be used therapeutically when overexpression of a miRNA contributes to a disease state. Chemical modification of synthetic AMOs enhance potency by protecting the oligonucleotide from nuclease degradation and by increasing binding affinity to the target miRNA. A new steric-blocking ASO modification strategy with favorable properties for use in AMOs was recently developed that combines use of high-affinity 2'-O-methyl RNA with terminally positioned non-nucleotide "ZEN" modifiers. This protocol describes use of ZEN AMOs in a dual-luciferase reporter assay as a simplified means to validate AMO performance or to quickly test putative miRNA binding sites in target sequences. This protocol also describes a method using Western blot analysis for quantifying the level of upregulation of proteins made from an mRNA that is thought to be under miRNA regulation, following inhibition of that miRNA by ZEN AMO treatment.

Entities:  

Keywords:  Chemical modifications; Inhibitors; Knockdown; MARCKS; Non-nucleotide modifier; Oligonucleotides; PTEN; Western blot; ZEN; miR); miR-21; microRNAs (miRNA

Mesh:

Substances:

Year:  2017        PMID: 27924473     DOI: 10.1007/978-1-4939-6563-2_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

Review 1.  Advances in therapeutic bacterial antisense biotechnology.

Authors:  John P Hegarty; David B Stewart
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-05       Impact factor: 4.813

Review 2.  Alzheimer's Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target.

Authors:  Meng Zhang; Zhigang Bian
Journal:  Front Neurosci       Date:  2021-05-24       Impact factor: 4.677

3.  Exploring the tissue tropism of pseudorabies virus based on miRNA level analysis.

Authors:  Yi Fan; Ling Zhu; Xiangang Sun; Wenting Lyu; Lei Xu; Yue Yin; Jun Zhao; Jianbo Huang; Yichao Den; Zhiyi Jiang; Shiyao Xu; Xiyu Mao; Zhiwen Xu
Journal:  BMC Microbiol       Date:  2019-06-11       Impact factor: 3.605

4.  Expression characteristics of pineal miRNAs at ovine different reproductive stages and the identification of miRNAs targeting the AANAT gene.

Authors:  Ran Di; Qiu-Yue Liu; Shu-Hui Song; Dong-Mei Tian; Jian-Ning He; Ying Ge; Xiang-Yu Wang; Wen-Ping Hu; Joram-Mwashigadi Mwacharo; Zhang-Yuan Pan; Jian-Dong Wang; Qing Ma; Gui-Ling Cao; Hui-Hui Jin; Xiao-Jun Liang; Ming-Xing Chu
Journal:  BMC Genomics       Date:  2021-03-25       Impact factor: 3.969

Review 5.  miRNAs in Cancer (Review of Literature).

Authors:  Beata Smolarz; Adam Durczyński; Hanna Romanowicz; Krzysztof Szyłło; Piotr Hogendorf
Journal:  Int J Mol Sci       Date:  2022-03-03       Impact factor: 5.923

6.  Bulge-Forming miRNases Cleave Oncogenic miRNAs at the Central Loop Region in a Sequence-Specific Manner.

Authors:  Olga Patutina; Daria Chiglintseva; Bahareh Amirloo; David Clarke; Svetlana Gaponova; Valentin Vlassov; Elena Bichenkova; Marina Zenkova
Journal:  Int J Mol Sci       Date:  2022-06-12       Impact factor: 6.208

7.  A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells.

Authors:  Christopher A Vakulskas; Daniel P Dever; Garrett R Rettig; Rolf Turk; Ashley M Jacobi; Michael A Collingwood; Nicole M Bode; Matthew S McNeill; Shuqi Yan; Joab Camarena; Ciaran M Lee; So Hyun Park; Volker Wiebking; Rasmus O Bak; Natalia Gomez-Ospina; Mara Pavel-Dinu; Wenchao Sun; Gang Bao; Matthew H Porteus; Mark A Behlke
Journal:  Nat Med       Date:  2018-08-06       Impact factor: 53.440

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.